Adjuvant chemotherapy with TAC (docetaxel, doxorubicin, and cyclophosphamide) in patients with breast cancer - Incidence of neutropenic fever outside clinical trials

Breast Journal

Volumn 17, Issue 5, 2011, Pages 539-541

  Passos Coelho, Jose L ^a   Esteves, Susana ^a   Vieira, Paula A ^a   Isidoro, Miguel ^a   Ribeiro, Manuel ^a   Oliveira, João ^a   Moreira, Antõnio R ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST CARCINOMA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PARTIAL MASTECTOMY; THERAPY DELAY; TREATMENT DURATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 80052559357     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01140.x     Document Type: Letter

References (5)

1. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352: 2302-13. (Pubitemid 40740554)
2. Martin M, Lluch A, Segui M, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant TAC or FAC: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17: 1205-12. (Pubitemid 44288210)
3. Nabholtz JM, Cantin J, Chang J, et al. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel, doxorubicin, cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer 2002; 3: 268-75. (Pubitemid 35423147)
4. von Minckwitz G, Kümmel S, du Bois A, et al. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol 2008; 19: 292-8. (Pubitemid 351201710)
5. Gafter-Gvili A, Fraser A, Paul M, Leibovici L,. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95. (Pubitemid 40840313)